All In Biotech

Drug Trial Radar · NCT00793624

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I

A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 ug] and 10 ug [2 Actuations of 5 ug]) Delivered by the Respimat® Inhaler, and 48 Weeks of Twice Daily Foradil® (12 µg) Delivered by the Aerolizer® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 19, 2026Latest source record: Jun 27, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 906 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

906

Actual

Start

Feb 2009

Primary completion

Dec 2010

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Nov 19, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the long-term efficacy and safety of once daily treatment of BI 1744 CL inhalation solution (5 and 10 mcg) delivered via the Respimat® inhaler, in patients with COPD.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • Olodaterol (BI 1744)Drug

    Comparison of low and high doses on efficacy and safety in COPD patients

  • Olodaterol (BI 1744)Drug

    Comparison of low and high doses on efficacy and safety in COPD patients

  • FormoterolDrug

    Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients

  • PlaceboDrug

    Placebo for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients

  • PlaceboDrug

    Placebo for comparison Formoterolon safety and efficacy in COPD patients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 24 WeeksTime frame: 1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 24
  2. Trough FEV1 Response at Week 24Time frame: 1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 24.
  3. Mahler Transitional Dyspnea Index Focal Score at 24 WeeksTime frame: Baseline, Week 24
  4. Mahler Transitional Dyspnea Index Focal Score at 24 Weeks for Combined AnalysisTime frame: Baseline, Week 24

Locations

93 sites in 20 countries. Site status is shown where the registry gives one.

  • 1222.13.2401 Boehringer Ingelheim Investigational Site

    Capital Federal, Argentina

  • 1222.13.2403 Boehringer Ingelheim Investigational Site

    Capital Federal, Argentina

  • 1222.13.2402 Boehringer Ingelheim Investigational Site

    Mar del Plata, Argentina

  • 1222.13.2404 Boehringer Ingelheim Investigational Site

    Monte Grande, Argentina

  • 1222.13.2502 Boehringer Ingelheim Investigational Site

    Juiz de Fora, Brazil

  • 1222.13.2503 Boehringer Ingelheim Investigational Site

    Rio de Janeiro, Brazil

  • 1222.13.2505 Boehringer Ingelheim Investigational Site

    Rio de Janeiro, Brazil

  • 1222.13.2501 Boehringer Ingelheim Investigational Site

    São Paulo, Brazil

  • 1222.13.2504 Boehringer Ingelheim Investigational Site

    São Paulo, Brazil

  • 1222.13.1408 Boehringer Ingelheim Investigational Site

    Calgary, Alberta, Canada

  • 1222.13.1407 Boehringer Ingelheim Investigational Site

    Chilliwack, British Columbia, Canada

  • 1222.13.1403 Boehringer Ingelheim Investigational Site

    Downsview, Ontario, Canada

  • 1222.13.1412 Boehringer Ingelheim Investigational Site

    Hamilton, Ontario, Canada

  • 1222.13.1401 Boehringer Ingelheim Investigational Site

    Niagara Falls, Ontario, Canada

  • 1222.13.1410 Boehringer Ingelheim Investigational Site

    Sarnia, Ontario, Canada

  • 1222.13.1413 Boehringer Ingelheim Investigational Site

    Toronto, Ontario, Canada

  • 1222.13.1404 Boehringer Ingelheim Investigational Site

    La Malbaie, Quebec, Canada

  • 1222.13.1411 Boehringer Ingelheim Investigational Site

    Montreal, Quebec, Canada

  • 1222.13.1406 Boehringer Ingelheim Investigational Site

    Point Claire, Quebec, Canada

  • 1222.13.1402 Boehringer Ingelheim Investigational Site

    Saskatoon, Saskatchewan, Canada

  • 1222.13.3502 Boehringer Ingelheim Investigational Site

    Dubrovnik, Croatia

  • 1222.13.3503 Boehringer Ingelheim Investigational Site

    Rijeka, Croatia

  • 1222.13.3504 Boehringer Ingelheim Investigational Site

    Split, Croatia

  • 1222.13.3501 Boehringer Ingelheim Investigational Site

    Zagreb, Croatia

  • 1222.13.3401 Boehringer Ingelheim Investigational Site

    Beroun, Czechia

  • 1222.13.3403 Boehringer Ingelheim Investigational Site

    Český Těšín, Czechia

  • 1222.13.3402 Boehringer Ingelheim Investigational Site

    Tábor, Czechia

  • 1222.13.2003 Boehringer Ingelheim Investigational Site

    Aalborg, Denmark

  • 1222.13.2002 Boehringer Ingelheim Investigational Site

    Hvidovre, Denmark

  • 1222.13.2001 Boehringer Ingelheim Investigational Site

    Silkeborg, Denmark

  • 1222.13.2103 Boehringer Ingelheim Investigational Site

    Lahti, Finland

  • 1222.13.2101 Boehringer Ingelheim Investigational Site

    Tampere, Finland

  • 1222.13.2102 Boehringer Ingelheim Investigational Site

    Turku, Finland

  • 1222.13.1502 Boehringer Ingelheim Investigational Site

    Berlin, Germany

  • 1222.13.1503 Boehringer Ingelheim Investigational Site

    Berlin, Germany

  • 1222.13.1506 Boehringer Ingelheim Investigational Site

    Berlin, Germany

  • 1222.13.1501 Boehringer Ingelheim Investigational Site

    Cologne, Germany

  • 1222.13.1511 Boehringer Ingelheim Investigational Site

    Dortmund, Germany

  • 1222.13.1514 Boehringer Ingelheim Investigational Site

    Essen, Germany

  • 1222.13.1509 Boehringer Ingelheim Investigational Site

    Großhansdorf, Germany

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.